Candriam S.C.A. Grows Stock Position in Ultragenyx Pharmaceutical Inc. $RARE

Candriam S.C.A. lifted its holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 43.4% during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 754,714 shares of the biopharmaceutical company’s stock after purchasing an additional 228,447 shares during the period. Candriam S.C.A.’s holdings in Ultragenyx Pharmaceutical were worth $22,702,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in RARE. Covestor Ltd increased its holdings in Ultragenyx Pharmaceutical by 26.0% during the third quarter. Covestor Ltd now owns 1,787 shares of the biopharmaceutical company’s stock valued at $54,000 after buying an additional 369 shares during the last quarter. Teacher Retirement System of Texas increased its stake in shares of Ultragenyx Pharmaceutical by 1.8% in the 2nd quarter. Teacher Retirement System of Texas now owns 22,773 shares of the biopharmaceutical company’s stock worth $828,000 after purchasing an additional 404 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in Ultragenyx Pharmaceutical by 2.3% in the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 18,988 shares of the biopharmaceutical company’s stock worth $690,000 after purchasing an additional 434 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. lifted its position in Ultragenyx Pharmaceutical by 7.0% during the second quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 6,783 shares of the biopharmaceutical company’s stock valued at $247,000 after purchasing an additional 441 shares in the last quarter. Finally, DNB Asset Management AS grew its holdings in Ultragenyx Pharmaceutical by 3.2% during the second quarter. DNB Asset Management AS now owns 14,720 shares of the biopharmaceutical company’s stock valued at $535,000 after purchasing an additional 452 shares during the period. 97.67% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research firms have recently commented on RARE. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, January 21st. Wells Fargo & Company lowered their price target on shares of Ultragenyx Pharmaceutical from $65.00 to $45.00 and set an “overweight” rating on the stock in a report on Tuesday, December 30th. Guggenheim dropped their price target on shares of Ultragenyx Pharmaceutical from $64.00 to $52.00 and set a “buy” rating for the company in a research report on Monday, January 5th. Robert W. Baird decreased their price objective on shares of Ultragenyx Pharmaceutical from $72.00 to $47.00 and set an “outperform” rating on the stock in a research report on Tuesday, December 30th. Finally, TD Cowen dropped their target price on shares of Ultragenyx Pharmaceutical from $86.00 to $75.00 and set a “buy” rating for the company in a report on Wednesday, November 5th. Sixteen investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Ultragenyx Pharmaceutical presently has an average rating of “Moderate Buy” and an average price target of $72.29.

Insider Activity

In related news, CFO Howard Horn sold 3,061 shares of the business’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $23.56, for a total value of $72,117.16. Following the sale, the chief financial officer directly owned 88,935 shares in the company, valued at approximately $2,095,308.60. The trade was a 3.33% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders sold 6,227 shares of company stock valued at $187,126 over the last quarter. Insiders own 5.50% of the company’s stock.

More Ultragenyx Pharmaceutical News

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: Ultragenyx’s gene therapy shows long‑term efficacy in two Sanfilippo studies — supports durability of clinical benefit and strengthens the therapy’s commercial/clinical case, a medium/long‑term positive for RARE. BioSpace Article
• Neutral Sentiment: Quant snapshot placed Ultragenyx among lagging names in a market buy/sell screen — indicates short‑term positioning flows but not a new company-specific development. MSN Quant Snapshot
• Negative Sentiment: Multiple plaintiff firms have filed or posted notices about a class action covering purchases from Aug 3, 2023 to Dec 26, 2025 and are soliciting lead plaintiffs (lead‑plaintiff deadline April 6, 2026). The surge of filings/solicitations (Rosen Law, Faruqi & Faruqi, Robbins LLP, DJS Law Group, Schall Law Firm, Bronstein Gewirtz & Grossman, etc.) increases legal risk, potential settlement exposure, and creates investor uncertainty/near‑term selling pressure. Links: Rosen Law release Rosen Law, Faruqi & Faruqi notice Faruqi, Robbins LLP reminder Robbins LLP, DJS Law Group notice DJS, Schall Law Firm Schall, Bronstein notice Bronstein.

Ultragenyx Pharmaceutical Stock Performance

Shares of NASDAQ RARE opened at $23.88 on Tuesday. The company has a market cap of $2.30 billion, a P/E ratio of -4.02 and a beta of 0.16. Ultragenyx Pharmaceutical Inc. has a 52-week low of $18.41 and a 52-week high of $46.27. The firm’s fifty day moving average is $27.93 and its two-hundred day moving average is $29.89.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.